Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 Trial
No Thumbnail Available
Authors
Post C.C.B.
de Boer S.M.
Powell M.E.
Mileshkin L.
Katsaros D.
Bessette P.
Leary A.
Ottevanger P.B.
McCormack M.
Khaw P.
Check for full-text access
Issue Date
2025
Type
Article
Language
Keywords
Alternative Title
Abstract
(Abstracted from Lancet Oncol 2025;26(10):1370-1381) Fifteen percent to 20% of endometrial cancer patients have a high-risk form of the disease; this classification indicates a higher risk of cancer recurrence and cancer-related death. The standard therapy for high-risk endometrial cancer is pelvic radiotherapy. Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Description
Citation
Publisher
License
Journal
Obstetrical & gynecological survey
Volume
80
Issue
12